These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 24365257

  • 21. Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.
    Li Z, Habuchi T, Mitsumori K, Kamoto T, Kinoshitu H, Segawa T, Ogawa O, Kato T.
    J Urol; 2003 Jun; 169(6):2378-81. PubMed ID: 12771801
    [Abstract] [Full Text] [Related]

  • 22. Association of V89L SRD5A2 polymorphism with craving and serum leptin levels in male alcohol addicts.
    Lenz B, Schöpp E, Müller CP, Bleich S, Hillemacher T, Kornhuber J.
    Psychopharmacology (Berl); 2012 Dec; 224(3):421-9. PubMed ID: 22707254
    [Abstract] [Full Text] [Related]

  • 23. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
    Spurdle AB, Hopper JL, Chen X, Dite GS, McCredie MR, Giles GG, Venter DJ, Southey MC, Purdie DM, Chenevix-Trench G.
    Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447
    [Abstract] [Full Text] [Related]

  • 24. [V89L polymorphism of the testosterone 5-alpha-reductase II gene and prognostic factors of prostate cancer].
    Tong M, Jin YY, Li G, Liu SM, Ji CD.
    Zhonghua Nan Ke Xue; 2010 Nov; 16(11):990-3. PubMed ID: 21218640
    [Abstract] [Full Text] [Related]

  • 25. Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population.
    Rahimi M, Ghanbari M, Fazeli Z, Rouzrokh M, Omrani S, Mirfakhraie R, Omrani MD.
    J Endocrinol Invest; 2017 Apr; 40(4):391-396. PubMed ID: 27848231
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer.
    Chang BL, Zheng SL, Isaacs SD, Turner AR, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J.
    Prostate; 2003 Jun 15; 56(1):37-44. PubMed ID: 12746845
    [Abstract] [Full Text] [Related]

  • 28. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
    Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ.
    Clin Cancer Res; 2008 May 15; 14(10):3223-9. PubMed ID: 18483391
    [Abstract] [Full Text] [Related]

  • 29. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
    Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, Mohan H.
    DNA Cell Biol; 2006 May 15; 25(5):287-94. PubMed ID: 16716118
    [Abstract] [Full Text] [Related]

  • 30. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
    Li J, Coates RJ, Gwinn M, Khoury MJ.
    Am J Epidemiol; 2010 Jan 01; 171(1):1-13. PubMed ID: 19914946
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.
    Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G.
    Eur Urol; 2005 Oct 01; 48(4):679-85. PubMed ID: 16039774
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS, Conti DV, Curran A, Neville PJ, Paris PL, Casey G, Witte JS.
    Prostate; 2004 Apr 01; 59(1):69-76. PubMed ID: 14991867
    [Abstract] [Full Text] [Related]

  • 35. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
    Rossi L, Leveri M, Gritti C, De Silvestri A, Zavaglia C, Sonzogni L, Silvestri L, Civardi E, Mondelli MU, Silini EM.
    J Hepatol; 2003 Oct 01; 39(4):564-70. PubMed ID: 12971967
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The association of 5-alpha reductase type 2 (SRD5A2) gene polymorphisms with prostate cancer in a Korean population.
    Choi SY, Kim HJ, Cheong HS, Myung SC.
    Korean J Urol; 2015 Jan 01; 56(1):19-30. PubMed ID: 25598933
    [Abstract] [Full Text] [Related]

  • 38. Analysis of polymorphisms in the SRD5A2 gene and semen parameters in Estonian men.
    Peters M, Saare M, Kaart T, Haller-Kikkatalo K, Lend AK, Punab M, Metspalu A, Salumets A.
    J Androl; 2010 Jan 01; 31(4):372-8. PubMed ID: 19926884
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Genetic determinants of anatomical variants of the prostate].
    Hamadeh H, Larré S, Azzouzi AR, Cancel-Tassin G, Vallancien G, Cochand-Priollet B, Cussenot O.
    Prog Urol; 2008 Apr 01; 18(4):214-22. PubMed ID: 18501301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.